Abstract
Background. 131-I-metaiodobenzylguanidine is a radioiodinated compound selectively concentrated by cells of neuroectodermal origin, including neuroblastoma cells, for this reason it may represent a promising treatment modality for neuroblastoma in childhood. Although a potential side effect of 131-I-MIBG administration is thyroid dysfunction, relatively few data are reported about this issue. Methods. A series of 14 long term surviving patients with neuroblastoma who had been treated with 131-I-MIBG courses ranging from 2.5 to 5.5 gigabecquerels after surgical and conventional pharmacologic therapy is reported. Results. Twelve patients developed primary hypothyroidism that was clinically overt in 8 patients and compensated in 4 patients within 6-12 months of completion of 131-I-MIBG administration. Only in two patients was thyroid function spared. Significant correlations between the cumulative dose of 131-I-MIBG and the degree of thyroid failure were not found. Conclusions. Primary hypothyroidism appears to be a common side effect in children with neuroblastoma treated with 131-I-MIBG. This finding suggests that methods to preserve thyroid function other than oral administration of iodide should be sought.
| Original language | English |
|---|---|
| Pages (from-to) | 1662-1664 |
| Number of pages | 3 |
| Journal | Cancer |
| Volume | 76 |
| Issue number | 9 |
| DOIs | |
| Publication status | Published - 1995 |
Fingerprint
Keywords
- 131-I-metaiodobenzylguanidine (MIBG)
- late effects
- neuroblastoma
- primary hypothyroidism
ASJC Scopus subject areas
- Cancer Research
- Oncology
Cite this
Primary hypothyroidism as a consequence of 131-I-metaiodobenzylguanidine treatment for children with neuroblastoma. / Picco, P.; Garaventa, A.; Claudiani, F.; Gattorno, M.; De Bernardi, B.; Borrone, C.
In: Cancer, Vol. 76, No. 9, 1995, p. 1662-1664.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Primary hypothyroidism as a consequence of 131-I-metaiodobenzylguanidine treatment for children with neuroblastoma
AU - Picco, P.
AU - Garaventa, A.
AU - Claudiani, F.
AU - Gattorno, M.
AU - De Bernardi, B.
AU - Borrone, C.
PY - 1995
Y1 - 1995
N2 - Background. 131-I-metaiodobenzylguanidine is a radioiodinated compound selectively concentrated by cells of neuroectodermal origin, including neuroblastoma cells, for this reason it may represent a promising treatment modality for neuroblastoma in childhood. Although a potential side effect of 131-I-MIBG administration is thyroid dysfunction, relatively few data are reported about this issue. Methods. A series of 14 long term surviving patients with neuroblastoma who had been treated with 131-I-MIBG courses ranging from 2.5 to 5.5 gigabecquerels after surgical and conventional pharmacologic therapy is reported. Results. Twelve patients developed primary hypothyroidism that was clinically overt in 8 patients and compensated in 4 patients within 6-12 months of completion of 131-I-MIBG administration. Only in two patients was thyroid function spared. Significant correlations between the cumulative dose of 131-I-MIBG and the degree of thyroid failure were not found. Conclusions. Primary hypothyroidism appears to be a common side effect in children with neuroblastoma treated with 131-I-MIBG. This finding suggests that methods to preserve thyroid function other than oral administration of iodide should be sought.
AB - Background. 131-I-metaiodobenzylguanidine is a radioiodinated compound selectively concentrated by cells of neuroectodermal origin, including neuroblastoma cells, for this reason it may represent a promising treatment modality for neuroblastoma in childhood. Although a potential side effect of 131-I-MIBG administration is thyroid dysfunction, relatively few data are reported about this issue. Methods. A series of 14 long term surviving patients with neuroblastoma who had been treated with 131-I-MIBG courses ranging from 2.5 to 5.5 gigabecquerels after surgical and conventional pharmacologic therapy is reported. Results. Twelve patients developed primary hypothyroidism that was clinically overt in 8 patients and compensated in 4 patients within 6-12 months of completion of 131-I-MIBG administration. Only in two patients was thyroid function spared. Significant correlations between the cumulative dose of 131-I-MIBG and the degree of thyroid failure were not found. Conclusions. Primary hypothyroidism appears to be a common side effect in children with neuroblastoma treated with 131-I-MIBG. This finding suggests that methods to preserve thyroid function other than oral administration of iodide should be sought.
KW - 131-I-metaiodobenzylguanidine (MIBG)
KW - late effects
KW - neuroblastoma
KW - primary hypothyroidism
UR - http://www.scopus.com/inward/record.url?scp=0028822146&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0028822146&partnerID=8YFLogxK
U2 - 10.1002/1097-0142(19951101)76:9<1662::AID-CNCR2820760924>3.0.CO;2-V
DO - 10.1002/1097-0142(19951101)76:9<1662::AID-CNCR2820760924>3.0.CO;2-V
M3 - Article
C2 - 8635072
AN - SCOPUS:0028822146
VL - 76
SP - 1662
EP - 1664
JO - Cancer
JF - Cancer
SN - 0008-543X
IS - 9
ER -